期刊文献+

苯甲酸阿格列汀关键中间体合成工艺改进 被引量:3

Improved Synthesis of the Key Intermediate of Alogliptin Benzoate
下载PDF
导出
摘要 报道了苯甲酸阿格列汀的关键中间体(R)-2-[(6-(3-Boc-氨基哌啶-1-基)-3-甲基-2,4-二氧代-3,4-二氢嘧啶-1(2H)-基)甲基]苄腈的合成方法,通过优化反应溶剂和缚酸剂,改进投料用量,有效避免了反应杂质生成的同时降低了反应成本,使路线更加适合工业化生产。 A new method was reported for synthesis of 2-({6-[(3R)-3-Boc-piperidin-1-y-l]-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile, which is the key intermedi-ate of Alogliptin benzoate.Being well optimized, the improved process has the merits of low cost, less impurities and simple operation to meet the needs of industrial production.
出处 《浙江化工》 CAS 2016年第2期17-19,共3页 Zhejiang Chemical Industry
关键词 苯甲酸阿格列汀 中间体 异丙醇 工艺优化 alogliptin benzoate intermediate isopropyl alcohol process optimization
  • 相关文献

参考文献10

  • 1Olefsky J M.Diabetes M.Cecil te-xbook of medicine[M].19th edition.W.B.un-ders Company,Philadelphia,1992:1291.
  • 2Shaw J E,Sicree R A,Zimmet P Z.Global esti-mates of the prevalence of diabetes for 2010 and 2030[J].Diabetes Res Clin Pr.,2010,87(1):4-14.
  • 3Feng,Jun.et al.Dipeptidyl peptidase inhibitor:EP,1586571A[P].2005-10-19.
  • 4李明杰,刘新泉,李晓峰,等.苯甲酸阿格列汀的制备方法:中国,103193762[P].2013-07-10.
  • 5Feng J,Gwaltney S L,Stafford J A,et al.Dipe-ptidyl peptidase inhibitors:WO,2007035629[P].2006-09-15.
  • 6Zhang Z Y,Wallace M B,Feng J,et al.De-sign and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV[J].J Med Chem.,2011,54(2):510-524.
  • 7刘昭文,吴龙火,王恩军.苯甲酸阿格列汀的合成[J].海峡药学,2011,23(9):214-215. 被引量:18
  • 8崔翼,罗邻涛,周定康,等.一种苯甲酸阿格列汀的制备工艺:中国,102942556[P].2013-02-27.
  • 9Marom E,Mizhiritskii M,Rubnov S H.Process for the preparation of alogliptin and its salts using cyclocondensation as key step:WO,2010109468A1[P].2010-09-30.
  • 10Vadali L R,Dasar i S R,et al.Process for preparation of alogliptin:WO,2015092739[P].2015-06-25.

二级参考文献6

共引文献17

同被引文献25

  • 1崔翼,罗邻涛,周定康,等.一种苯甲酸阿格列汀的制备工艺:中国,102942556[P].2013-02-27.
  • 2李明杰,刘新泉,李晓峰,等.苯甲酸阿格列汀的制备方法:中国,103193762[P].2013-07-10.
  • 3Thomas G, Volker K, Ulrich J. Griesser. Alogliptin and its benzoate salt[J]. Acta Cryst, 2013,C69:674 - 678.
  • 4Lucienne J J. Dipeptidyl peptidase IV and its inhibitors: Therapeutics for type 2 diabetes and what else?[J]. J Med Chem, 2014,57:2197-2212.
  • 5Thomas L, Eekhardt M, Langkopf E. (R)-8-(3-amino-pipefidin-1-yl) -7-but-2-ynyl-3-methyl- 1-(4-meth-ylquinazolin-2-ylmethyl)-3, 7- dihydro- purine- 2,6- dione(BI1356), a novel xanthine- based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase 4 inhibitor[J]. J Pharmacol Exp Ther, 2008,325(1): 175-182.
  • 6Bumsup L, Lihong S, Daniel B. Pharmacokinetic, pharmcodynamie,and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs and monkeys[J]. Eur J Pharmacol, 2008,589( 1/3):306-314.
  • 7Covington P, Christopher R, Daven- port M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, dou ble-blind, placebo-controlled, multiple- dose study in adult patients with type 2 diabetes[J]. Clin Ther, 2008,30(3):499-512.
  • 8Scott L J. Alogliptin: a review of its use in the management of type 2 diabetes mellitus[J]. Drugs, 2010,70(15):2051-2072.
  • 9Feng J. Dipeptidyl peptidase inhibitor: EP,1586571A[P]. 2005-10-19.
  • 10Feng J, Gwahney S L, Stafford J A. Dipeptidyl peptidase inhibitors: WO,2007035629[P]. 2006-09-15.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部